Edition:
United Kingdom

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

10.29USD
15 Dec 2017
Change (% chg)

$0.22 (+2.18%)
Prev Close
$10.07
Open
$10.02
Day's High
$10.34
Day's Low
$9.41
Volume
47,914
Avg. Vol
13,916
52-wk High
$15.34
52-wk Low
$9.41

Summary

Name Age Since Current Position

Joseph Yanchik

52 President, Chief Executive Officer, Director

Evan Lippman

2015 Chief Financial Officer and Business Officer, Senior Vice President

Manuel Aivado

2014 Senior Vice President and Chief Medical Officer

D. Allen Annis

2007 Vice President - Biophysical and Analytical Technologies

Seth Harrison

56 2016 Director

Biographies

Name Description

Joseph Yanchik

Mr. Joseph A. Yanchik, III is President, Chief Executive Officer, Director of Aileron Therapeutics, Inc. Prior to Aileron, Mr. Yanchik was a founder and CEO of Tokai Pharmaceuticals, Venture Partner at Apple Tree Partners, Vice President of Corporate Development at Mendel Biotechnology and founder and Chief Business Officer of Poetic Genetics, Inc. Mr. Yanchik previously specialized in corporate and securities law at Cahill Gordon & Reindel (New York, NY) and Venture Law Group (Menlo Park, CA). He is presently on the Board of Directors of Tokai Pharmaceuticals. Mr. Yanchik received a B.B.A. from Loyola College and received his J.D. with Honors from Villanova University School of Law, where he was Managing Editor of the Law Review.

Evan Lippman

Mr. Evan Lippman is Chief Financial Officer and Business Officer, Senior Vice President of the Company. He began his career in corporate finance and investment banking, managing equity, debt and M&A processes, working with such companies as Bank of America, and Bear Stearns. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono, Inc., leading the strategic direction of the US Neurology franchise, as well as managing its operations related to sales, marketing and support services. Mr. Lippman joined EMD Serono from AstraZeneca, where he served as Executive Director of the company’s multi-billion dollar brands, Crestor® and Nexium®, as well as the general Primary Care Portfolio. While at AstraZeneca, Mr. Lippman also held other roles including Head of US Business Development. Prior to AstraZeneca, he worked at Pfizer as Executive Director, Worldwide Business Development and Strategic Planning. Mr. Lippman holds a Bachelor of Arts in Political Science from Bucknell University, a Bachelor of Arts in Business from Georgia State University, and a Masters in Business Administration from Cornell University.

Manuel Aivado

Mr. Manuel C. Aivado is Senior Vice President and Chief Medical Officer of the Company. Prior to joining Aileron, Dr. Aivado served as Taiho Oncology’s Vice President of Clinical Development and Pharmacovigilance. In that capacity, he built global clinical development capabilities, and led multiple drug programs ranging from phase 1 through phase 3, most prominently the global development of Teysuno® (S-1), TAS-102 and TAS-120. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, including as Senior Medical Director in the Clinical Development group, where he was involved in numerous drug programs including ofatumumab (Arzerra®), trametinib (Mekinist®), pazopanib (Votrient®), and eltrombopag (Promacta®). Prior to his industry experience, Dr. Aivado practiced ten years of clinical medicine in Germany. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado’s work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology. Dr. Aivado is a German Board-certified physician for Internal Medicine, Hematology, and Medical Oncology, and he earned an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.

D. Allen Annis

Dr. D. Allen Annis, Ph.D. is the Vice President - Biophysical and Analytical Technologies of Aileron Therapeutics, Inc. He has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions. Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.

Seth Harrison

Dr. Seth L. Harrison, M.D. is the Director of Aileron Therapeutics, Inc. He is the Founder and Managing General Partner of Apple Tree Partners. He serves on the Board of Directors of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides. Dr. Harrison received a Bachelor of Arts from Princeton University, a Doctor of Medicine and Master of Business Administration from Columbia University and completed a surgery internship at the New York Presbyterian Hospital.

Basic Compensation

Options Compensation